Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
Kohei Shitara,Keisho Chin,Takaki Yoshikawa,Hitoshi Katai,Masanori Terashima,Seiji Ito,Motohiro Hirao,Kazuhiro Yoshida,Eiji Oki,Mitsuru Sasako,Yasunori Emi,Toshimasa Tsujinaka +11 more
TLDR
S-1 and oxaliplatin therapy is suggested to be manageable and safe with optimal dose reduction and delay in selected patients for stage III gastric cancer after D2 gastrectomy, and warrants further evaluation in larger studies.Abstract:
Background
The Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC) demonstrated a survival benefit by adjuvant S-1 monotherapy in patients who had undergone curative resection of stage II/III gastric cancer, but there is still a need to improve the efficacy of treatment of stage III disease. We investigated the tolerability and safety of S-1 and oxaliplatin as adjuvant chemotherapy for stage III gastric cancer.read more
Citations
More filters
Journal ArticleDOI
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial
Xiaotian Zhang,Han Liang,Ziyu Li,Yingwei Xue,Yanong Wang,Zhiwei Zhou,J Yu,Zhaode Bu,Lin Chen,Yian Du,Xinbao Wang,Aiwen Wu,Guoli Li,Xiangqian Su,Gang Xiao,Ming Cui,Dan Wu,Chen Li,Xiaojiang Wu,Yanbing Zhou,Lianhai Zhang,Chengxue Dang,Yulong He,Zhongtao Zhang,Yihong Sun,Yong Li,Huanqiu Chen,Yuxian Bai,Changsong Qi,Peiwu Yu,Guanbao Zhu,Jian Suo,Baoqing Jia,Leping Li,Chang-Ming Huang,Fei Li,Yingjiang Ye,Huimian Xu,Xin Wang,Yannan Yuan,Jian-Yu E,Xiangji Ying,Chen Yao,Lin Shen,Jiafu Ji +44 more
TL;DR: In this article, the authors evaluated the efficacy and safety of perioperative and postoperative S-1 and oxaliplatin (SOX) compared with postoperative capecitabine (CAPO) in patients with locally advanced gastric cancer undergoing D2 gastrectomy.
Journal ArticleDOI
Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives
Masanori Tokunaga,Yuya Sato,Masatoshi Nakagawa,Tomoki Aburatani,Takatoshi Matsuyama,Yasuaki Nakajima,Yusuke Kinugasa +6 more
TL;DR: Preoperative neoadjuvant chemotherapy is a promising treatment strategy and likely to become standard treatment for locally advanced gastric cancer in Japan.
Journal ArticleDOI
Piperlongumine potentiates the antitumor efficacy of oxaliplatin through ROS induction in gastric cancer cells.
Peichen Zhang,Lingyan Shi,Tingting Zhang,Lin Hong,Wei He,Peihai Cao,Xin Shen,Peisen Zheng,Yiqun Xia,Peng Zou +9 more
TL;DR: P Piperlongumine (PL), an alkaloid isolated from Piper longum L., has recently been identified as a potent agent against cancer cells in vitro and in vivo and it is found that application of its combination may be more effective for the treatment of gastric cancer than oxaliplatin alone.
Journal ArticleDOI
Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy
Yoshiaki Nakamura,Takeharu Yamanaka,Keisho Chin,Haruhiko Cho,Hitoshi Katai,Masanori Terashima,Kazunari Misawa,Motohiro Hirao,Kazuhiro Yoshida,Eiji Oki,Mitsuru Sasako,Yasunori Emi,Hideaki Bando,Yoshiyuki Kawashima,Tetsu Fukunaga,Masahiro Gotoh,Takako Ishibashi,Kohei Shitara +17 more
TL;DR: This exploratory analysis demonstrated that SOX and CAPOX are suggested to have similar efficacy for pStage 3 GC patients after D2 gastrectomy, and differences in the treatment effect according to sex and histologic type warrant further evaluation.
Journal ArticleDOI
Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy
Kazumasa Fujitani,Shigeyuki Tamura,Yutaka Kimura,Takeshi Tsuji,Jin Matsuyama,Shohei Iijima,Hiroshi Imamura,Kentaro Inoue,Kenji Kobayashi,Yukinori Kurokawa,Toshio Shimokawa,Toshimasa Tsujinaka,Hiroshi Furukawa +12 more
TL;DR: On the basis of 3-year follow-up data, postoperative adjuvant therapy with S-1 plus docetaxel yielded promising OS and DFS in stage IIIA gastric cancer patients who had undergone D2 gastrectomy, and it is believed that this regimen is a candidate for future phase III trials studying the optimal adjUvant chemotherapy regimen for stage III Gastric cancer.
References
More filters
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet]
J Ferlay,I Soerjomataram,M Ervik,R Dikshit,S Eser,Colin Mathers,M Rebelo,D.M. Parkin,David Forman,Freddie Bray,S Elser,M Ervick,Donald Maxwell Parkin +12 more
Journal ArticleDOI
Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine
Shinichi Sakuramoto,M. Sasako,Toshiharu Yamaguchi,Taira Kinoshita,Masashi Fujii,Atsushi Nashimoto,Hiroshi Furukawa,Toshifusa Nakajima,Yasuo Ohashi,Hiroshi Imamura,Masayuki Higashino,Yoshitaka Yamamura,Akira Kurita,Kuniyoshi Arai +13 more
TL;DR: S-1 is an effective adjuvant treatment for East Asian patients who have undergone a D2 dissection for locally advanced gastric cancer and has a higher rate of overall survival than the surgery-only group.
Journal ArticleDOI
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
Yung-Jue Bang,Young-Woo Kim,Han-Kwang Yang,Hyun Cheol Chung,Young-Kyu Park,Kyung Hee Lee,Keun Wook Lee,Yong Ho Kim,Sang Ik Noh,Jae Yong Cho,Young Jae Mok,Yeul Hong Kim,Jiafu Ji,Ta Sen Yeh,Peter Button,Florin Sirzen,Sung Hoon Noh +16 more
TL;DR: Adjuvant capecitabine plus oxaliplatin treatment after curative D2 gastrectomy should be considered as a treatment option for patients with operable gastric cancer.
Journal ArticleDOI
Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer
Mitsuru Sasako,Shinichi Sakuramoto,Hitoshi Katai,Taira Kinoshita,Hiroshi Furukawa,Toshiharu Yamaguchi,Atsushi Nashimoto,Masashi Fujii,Toshifusa Nakajima,Yasuo Ohashi +9 more
TL;DR: On the basis of 5-year follow-up data, postoperative adjuvant therapy with S-1 was confirmed to improve overall survival and relapse-free survival in patients with stage II or III gastric cancer who had undergone D2 gastrectomy.